A detailed history of Vanguard Group Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,845,072 shares of RNA stock, worth $103 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,845,072
Previous 4,043,179 4.9%
Holding current value
$103 Million
Previous $36.6 Million 168.18%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$9.16 - $25.52 $1.81 Million - $5.06 Million
-198,107 Reduced 4.9%
3,845,072 $98.1 Million
Q4 2023

Feb 14, 2024

BUY
$4.87 - $9.37 $139,715 - $268,815
28,689 Added 0.71%
4,043,179 $36.6 Million
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $298,021 - $536,911
47,305 Added 1.19%
4,014,490 $25.6 Million
Q2 2023

Aug 14, 2023

BUY
$10.62 - $17.34 $5.16 Million - $8.42 Million
485,468 Added 13.94%
3,967,185 $44 Million
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $170,246 - $284,484
11,091 Added 0.32%
3,481,717 $53.4 Million
Q4 2022

Feb 10, 2023

BUY
$10.06 - $22.66 $7.77 Million - $17.5 Million
772,250 Added 28.62%
3,470,626 $77 Million
Q3 2022

Nov 14, 2022

BUY
$15.46 - $23.43 $4.27 Million - $6.47 Million
276,254 Added 11.41%
2,698,376 $44.1 Million
Q2 2022

Aug 12, 2022

BUY
$11.18 - $20.5 $1.38 Million - $2.54 Million
123,759 Added 5.38%
2,422,122 $35.2 Million
Q1 2022

May 13, 2022

BUY
$14.2 - $23.78 $4.19 Million - $7.01 Million
294,791 Added 14.71%
2,298,363 $42.5 Million
Q4 2021

Feb 14, 2022

BUY
$20.4 - $28.66 $1.24 Million - $1.75 Million
60,959 Added 3.14%
2,003,572 $47.6 Million
Q3 2021

Nov 12, 2021

BUY
$18.16 - $25.21 $12.2 Million - $16.9 Million
670,815 Added 52.75%
1,942,613 $47.8 Million
Q2 2021

Aug 13, 2021

BUY
$19.62 - $29.26 $25 Million - $37.2 Million
1,271,798 New
1,271,798 $31.4 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.4B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.